Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Researchers assessed changes among an aging population of people with chronic hepatitis C virus who are treated with DAAs, including the development of comorbidities and changes in liver disease severity.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
Numerous reports have indicated gastrointestinal, cardiovascular, and neurologic manifestations, in addition to the noted respiratory effects, in patients with COVID-19, and up to 50% of patients with COVID-19 may experience hepatic manifestations.